Try our mobile app
US Leaders — Screener 
Technology
Company / category Price and
change		 Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA		 AVG growth
last/hist		 EV/LTM EBITDA Express
potential		 Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
Apple 247.99 0.0% 0.4% 1.2% 
15.7% 
17.8%
16.7% 
5.2%
 25.9x
Google 298.79 0.0% 0.3% -0.1% 
15.9% 
13.3%
14.6% 
13.7%
 26.6x
Microsoft 381.87 0.0% 0.9% 1.2% 
16.7% 
23.4%
20.0% 
19.3%
 15.3x
Amazon 205.37 0.0% 0.0% 0.0% 
13.6% 
20.7%
17.2% 
26.1%
 14.5x
Facebook 593.66 0.0% 0.4% 0.0% 
23.8% 
8.4%
16.1% 
32.9%
 15.8x
Broadcom 309.86 -0.2% 0.8% 1.4% 
28.2% 
60.3%
44.3% 
24.8%
 57.3x
Netflix 91.82 0.0% 0.0% 2.2% 
17.2% 
11.6%
14.4% 
23.8%
 30.5x
Salesforce 195.38 0.0% 0.9% 0.8% 
8.6% 
11.0%
9.8% 
24.5%
 14.0x
Texas Instruments 187.19 0.0% 3.0% -1.0% 
10.4% 
12.0%
11.2% 
-6.0%
 22.4x
Adobe 248.15 0.0% 0.0% 1.2% 
10.5% 
12.4%
11.5% 
12.7%
 11.9x
Payments
Company / category Price and
change		 Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA		 AVG growth
last/hist		 EV/LTM EBITDA Express
potential		 Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
Visa 301.62 0.0% 0.8% --- 
11.5% 
-4.3%
3.6% 
6.5%
 28.3x
Mastercard 496.32 0.0% 0.6% --- 
17.6% 
21.5%
19.5% 
9.6%
 32.2x
Hardware
Company / category Price and
change		 Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA		 AVG growth
last/hist		 EV/LTM EBITDA Express
potential		 Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
Nvidia 172.70 0.0% 0.0% 0.7% 
73.2% 
83.5%
78.4% 
109.8%
 31.5x
QUALCOMM 129.90 0.0% 2.7% -0.1% 
5.0% 
-5.8%
-0.4% 
2.2%
 10.8x
Communications
Company / category Price and
change		 Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA		 AVG growth
last/hist		 EV/LTM EBITDA Express
potential		 Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
Cisco 77.65 0.0% 2.1% 1.5% 
7.5% 
26.1%
16.8% 
2.8%
 21.2x
Verizon 49.98 0.0% 5.5% 3.1% 
1.5% 
22.5%
12.0% 
4.2%
 7.4x
AT&T 28.31 0.0% 4.5% --- 
20.1% 
85.7%
52.9% 
56.8%
 4.7x
Comcast 29.02 0.0% 4.4% 4.0% 
-2.7% 
-1.9%
-2.3% 
9.4%
 5.8x
Entertainment
Company / category Price and
change		 Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA		 AVG growth
last/hist		 EV/LTM EBITDA Express
potential		 Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
Disney 99.51 0.0% 1.5% 0.1% 
5.2% 
-3.0%
1.1% 
26.1%
 12.0x
Consumer Brand
Company / category Price and
change		 Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA		 AVG growth
last/hist		 EV/LTM EBITDA Express
potential		 Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
Procter & Gamble 144.28 0.0% 2.9% -0.4% 
1.5% 
-4.3%
-1.4% 
5.3%
 16.6x
Coca-Cola 74.75 0.0% 2.7% -0.1% 
2.4% 
-30.4%
-14.0% 
7.0%
 24.0x
Philip Morris 163.11 0.0% 3.5% -0.4% 
9.4% 
14.8%
12.1% 
8.6%
 18.0x
PepsiCo 150.04 0.0% 3.8% -1.7% 
5.6% 
42.6%
24.1% 
6.0%
 15.9x
Nike 52.37 0.0% 3.1% -1.7% 
0.6% 
-27.8%
-13.6% 
-13.3%
 99.6x
Food
Company / category Price and
change		 Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA		 AVG growth
last/hist		 EV/LTM EBITDA Express
potential		 Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
McDonalds 308.85 0.0% 2.4% -0.5% 
3.0% 
0.2%
1.6% 
6.7%
 20.2x
Retail
Company / category Price and
change		 Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA		 AVG growth
last/hist		 EV/LTM EBITDA Express
potential		 Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
Walmart 119.02 0.0% 0.8% -0.5% 
5.6% 
10.8%
8.2% 
9.5%
 23.3x
Costco Wholesale 972.33 0.0% 0.5% 1.1% 
15.0% 
12.8%
13.9% 
9.3%
 33.2x
Home Depot 320.75 0.0% 2.9% 1.1% 
-3.8% 
-11.6%
-7.7% 
-0.9%
 16.2x
Pharma
Company / category Price and
change		 Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA		 AVG growth
last/hist		 EV/LTM EBITDA Express
potential		 Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
Eli Lilly 906.70 0.0% 0.7% -0.6% 
53.9% 
200.0%
126.9% 
44.0%
 34.0x
Johnson & Johnson 235.37 0.0% 2.2% -1.6% 
6.8% 
78.8%
42.8% 
16.4%
 16.6x
AbbVie 205.07 0.0% 3.2% -0.2% 
10.0% 
0.0%
5.0% 
-1.5%
 26.8x
Merck 114.18 0.0% 2.9% 0.1% 
3.7% 
49.7%
26.7% 
9.1%
 11.8x
United Health 275.59 0.0% 3.2% -3.4% 
12.2% 
-44.5%
-16.1% 
6.6%
 10.5x
Thermo Fisher Scientific 474.39 0.0% 0.4% -22.6% 
4.9% 
5.5%
5.2% 
-3.2%
 22.1x
Abbott 105.46 0.0% 2.3% 0.4% 
4.4% 
16.3%
10.4% 
2.0%
 20.9x
Pfizer 26.97 0.0% 6.4% 7.3% 
-5.9% 
-22.8%
-14.4% 
0.8%
 12.5x
Danaher 189.35 0.0% 0.7% 1.0% 
4.6% 
4.8%
4.7% 
-4.9%
 27.9x
Bristol-Myers Squibb 57.48 0.0% 4.3% 7.1% 
2.8% 
85.8%
44.3% 
-0.9%
 19.3x
Equipment
Company / category Price and
change		 Year div-d yield FCF Yield LTM Last growth
Revenue/EBITDA		 AVG growth
last/hist		 EV/LTM EBITDA Express
potential		 Next IFRS report Value Creation
Price +/- Revenue EBITDA Last Hist. (exp) (p75)
Tesla 367.96 0.0% 0.0% 0.7% 
11.6% 
-20.1%
-4.3% 
-0.4%
 107.3x
Raytheon Technologies 198.16 0.0% 1.3% 1.8% 
12.1% 
15.5%
13.8% 
14.4%
 23.7x
Market Attractiveness Index

Market Attractiveness Index

calculated as average express-upside for TOP-5 US companies with highest potential

High values of index (>30%), indicate favorable moments for additional cash contributions to the stock market / stock purchases

Current value of the Index is 99.6%

chart technology by TradingView

Portfolios

Invest in a rotating portfolio of top US-based, non-financial companies. Strategy results are shown below. This page contains financial information on the 40 companies we screen for our portfolio. For a detailed overview of our US Leaders strategy and rationale behind it, follow the link

US Leaders
since 2019-08-25

0.0%

-1.5%
day

-2.5%

-1.9%
week

+296.5%

128.5%
Since inception

0.0%

SP500
Since inception
KNOW MORE →

Target portfolio structure
Company Price Day change Week change target share Value Creation Web 3m traffic
57.48  0.0%  -3.7% 27.9% 52.3%
114.18  0.0%  -1.1% 21.7% 33.5%
77.65  0.0%  -1.6% 11.3% 17.4%
150.04  0.0%  -4.9% 11.2% 26.1%
381.87  0.0%  -4.5% 10.8% 16.7%
205.37  0.0%  -3.0% 9.5% 14.7%
105.46  0.0%  -4.1% 7.5% 11.6%
Actual Performance
Period Strategy SP&500
 
2019 +9.9% +13.5%
2020 +14.2% +16.2%
2021 +30.6% +27.4%
2022 -17.1% -19.7%
2023 +58.3% +24.2%
2024 +37.6% +23.5%
2025 +29.6% +16.4%
2026 +3.2% -5.1%
 
Annualized +23.3% +13.4%
 
Day 0.0% -1.5%
Week -2.5% -1.9%
Year to date +3.2% -5.1%
Since inception (2019-08-25) +296.5% +128.5%
Maximum drawdown
28.5%
Date of drawdown
2022-09-30
Sharpe ratio
1.1
Volatility (year)
17%
Portfolio (USD) and S&P500 dynamics (%)
chart technology by TradingView

Reviews

2026-03-22
(review)
Weekly results
for USD strategies

US Leaders: -2.5%

Global Commodities: -9.0%

Trending Ideas: -1.7%

Rising Stars: -8.5%

vs S&P500: -1.9%
2026-03-15
(review)
Weekly results
for USD strategies

US Leaders: -1.1%

Global Commodities: -1.4%

Trending Ideas: -0.1%

Rising Stars: +2.6%

vs S&P500: -1.6%
2026-03-08
(review)
Weekly results
for USD strategies

US Leaders: -3.3%

Global Commodities: -8.5%

Trending Ideas: -1.4%

Rising Stars: -6.3%

vs S&P500: -2.0%
2026-03-01
(review)
Weekly results
for USD strategies

US Leaders: +1.3%

Global Commodities: +2.8%

Trending Ideas: +0.6%

Rising Stars: +0.6%

vs S&P500: -0.4%
2026-02-28
#reports #ABT

Abbott (Medical products and equipment manufacturer ) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=8&id=131825)
(2026-01-22, Before Market Open):

- Revenue +4.4% YoY (vs +6.9% in previous quarter and historical rate +0.9%)
- EBITDA +16.3% YoY (vs +10.9% in previous quarter and historical rate +3.0%)
- EBITDA margin 22.9% increased compared to 20.5% same period last year
- Net Debt increased by $8 bln since the start of the year (3.9% of market cap)
- FCF (LTM) +$8.8 bln (positive), 4.3% of market cap
- EV/EBITDA multiple is 22.9x compared to historical level (75th percentile) of 27.4x
expected multiple is 22.1x

The company showed EPS +$3.74 per share. At the opening of the session the share price went down -13.9%

Growth potential changed insignificantly and equals +24.4%
2026-02-28
#reports #ABBV

AbbVie ( Medicines manufacturer) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195436)
(2026-02-04, Before Market Open):

- Revenue +10% YoY (vs +9.1% in previous quarter and historical rate +1.9%)
- EBITDA +474600% YoY (vs -47.9% in previous quarter and historical rate -4.9%)
- EBITDA margin 28.6% increased compared to -8.6% same period last year
- Net Debt decreased by $0.8 bln since the start of the year (0.2% of market cap)
- FCF (LTM) -$1.5 bln (negative), 0.4% of market cap
- EV/EBITDA multiple is 29.8x compared to historical level (75th percentile) of 37.6x
expected multiple is 44.3x

The company showed EPS +$2.38 per share. At the opening of the session the share price went down -7.0%

According to our model the company`s growth potential is negative
2026-02-26
#reports #NVDA

Nvidia (Developer of graphics processors) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=195101)
(2026-02-25, After Market Close):

- Revenue +73.2% YoY (vs +62.5% in previous quarter and historical rate +103.6%)
- EBITDA +83.5% YoY (vs +64.5% in previous quarter and historical rate +116.1%)
- EBITDA margin 66.2% increased compared to 62.5% same period last year
- Net Debt increased by $1.5 bln since the start of the year (0.0% of market cap)
- FCF (LTM) +$31.3 bln (positive), 0.7% of market cap
- EV/EBITDA multiple is 35.8x compared to historical level (75th percentile) of 69.9x
expected multiple is 34.5x
2026-02-26
#reports #LOW

Lowes Cos (Building materials seller) reported for 2025 q4
(2026-02-25, Before Market Open):

- Revenue +10.9% YoY (vs +3.2% in previous quarter and historical rate -3.5%)
- EBITDA -4.7% YoY (vs +1.6% in previous quarter and historical rate -7.2%)
- EBITDA margin 11.4% decreased compared to 13.3% same period last year
- Net Debt decreased by $0.3 bln since the start of the year (0.2% of market cap)
- FCF (LTM) +$2.8 bln (positive), 1.6% of market cap
- EV/EBITDA multiple is 17x compared to historical level (75th percentile) of 14.7x
2026-02-25
#reports #HD

Home Depot (Building materials and home improvement products retailer) reported for 2025 q4
(2026-02-24, Before Market Open):

- Revenue -3.8% YoY (vs +2.8% in previous quarter and historical rate +1.7%)
- EBITDA -11.6% YoY (vs 0.0% in previous quarter and historical rate -3.5%)
- EBITDA margin 12.3% decreased compared to 13.4% same period last year
- Net Debt increased by $6.7 bln since the start of the year (1.7% of market cap)
- FCF (LTM) +$10.2 bln (positive), 2.6% of market cap
- EV/EBITDA multiple is 18.9x compared to historical level (75th percentile) of 18.2x
expected multiple is 18.1x
2026-02-22
(review)
Weekly results
for USD strategies

US Leaders: +0.6%

Global Commodities: -1.3%

Trending Ideas: +1.0%

Rising Stars: -1.5%

vs S&P500: +1.1%
2026-02-20
#reports #WMT

Walmart (Chain of discount stores and supercenters) reported for 2025 q4
(2026-02-19, Before Market Open):

- Revenue +5.6% YoY (vs +5.8% in previous quarter and historical rate +5.3%)
- EBITDA +10.8% YoY (vs +3.4% in previous quarter and historical rate +13.7%)
- EBITDA margin 6.5% increased compared to 6.2% same period last year
- Net Debt decreased by $1.3 bln since the start of the year (0.1% of market cap)
- FCF (LTM) -$6.5 bln (negative), 0.6% of market cap
- EV/EBITDA multiple is 24.4x compared to historical level (75th percentile) of 19.9x
expected multiple is 24.9x
2026-02-15
(review)
Weekly results
for USD strategies

US Leaders: -1.9%

Global Commodities: +3.4%

Trending Ideas: +1.6%

Rising Stars: +3.8%

vs S&P500: -1.4%
2026-02-11
#reports #KO

Coca-Cola (Soft drinks poducer) reported for [2025 q4](https://eninvs.com/press_release.php?ticker=KO&q=2025 q4&id=915065)
(2026-02-10, Before Market Open):

- Revenue +2.4% YoY (vs +5.1% in previous quarter and historical rate +3.7%)
- EBITDA -30.4% YoY (vs +53.0% in previous quarter and historical rate +10.2%)
- EBITDA margin 17.6% decreased compared to 25.9% same period last year
- Net Debt decreased by $1.9 bln since the start of the year (0.6% of market cap)
- FCF (LTM) -$2.2 bln (negative), 0.7% of market cap
- EV/EBITDA multiple is 24.6x compared to historical level (75th percentile) of 27.9x
expected multiple is 20.5x
2026-02-11
#reports #GILD

Gilead Sciences (Medicines manufacturer) reported for 2025 q4
(2026-02-10, After Market Close):

- Revenue +4.7% YoY (vs +3.0% in previous quarter and historical rate +1.1%)
- EBITDA -15.6% YoY (vs +96800.0% in previous quarter and historical rate +5.5%)
- EBITDA margin 31.8% decreased compared to 39.5% same period last year
- Net Debt decreased by $1.3 bln since the start of the year (0.7% of market cap)
- FCF (LTM) +$0.6 bln (positive), 0.3% of market cap
- EV/EBITDA multiple is 19.4x compared to historical level (75th percentile) of 62.5x
2026-02-11
#reports #DD

DuPont (Chemical materials producer ) reported for [2025 q4](https://eninvs.com/press_release.php?ticker=DD&q=2025 q4&id=915050)
(2026-02-10, Before Market Open):

- Revenue -45.2% YoY (vs -3.8% in previous quarter and historical rate -8.4%)
- EBITDA -68.4% YoY (vs -26.1% in previous quarter and historical rate -17.0%)
- EBITDA margin 6.4% decreased compared to 11.1% same period last year
- Net Debt decreased by $4 bln since the start of the year (16.0% of market cap)
- FCF (LTM) +$0 bln (positive), 0.0% of market cap
- EV/EBITDA multiple is 21.2x compared to historical level (75th percentile) of 25.4x
2026-02-11
#reports #CVS

CVS health (Prescription drug provider) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=194812)
(2026-02-11, Before Market Open):

- Revenue +19.5% YoY (vs +4.2% in previous quarter and historical rate +21.0%)
- EBITDA +160.1% YoY (vs -20.7% in previous quarter and historical rate -13.7%)
- EBITDA margin 2.8% increased compared to 1.3% same period last year
- EV/EBITDA multiple is 15.5x compared to historical level (75th percentile) of 18.7x
2026-02-10
#reports #VZ

Verizon (Telecommunications company) reported for 2025 q4
(2026-01-30, Before Market Open):

- Revenue +287.3% YoY (vs +1.5% in previous quarter and historical rate +16.8%)
- EBITDA +300.1% YoY (vs +22.5% in previous quarter and historical rate +24.8%)
- EBITDA margin 34.5% increased compared to 33.4% same period last year
- Net Debt increased by $17.5 bln since the start of the year (9.0% of market cap)
- FCF (LTM) -$11.9 bln (negative), 6.1% of market cap
- EV/EBITDA multiple is 4.4x compared to historical level (75th percentile) of 8.4x
expected multiple is 6.7x

At the opening of the session the share price went up +5.5%

Growth potential increased by 199.2% to +245.1%
2026-02-10
#reports #UNH

United health (Biotechnology) reported for [2025 q4](https://eninvs.com/press_release.php?ticker=UNH&q=2025 q4&id=909407)
(2026-01-27, Before Market Open):

- Revenue +344% YoY (vs +12.2% in previous quarter and historical rate +27.0%)
- EBITDA +161.6% YoY (vs -44.5% in previous quarter and historical rate +13.1%)
- EBITDA margin 5.2% decreased compared to 8.7% same period last year
- Net Debt decreased by $9.3 bln since the start of the year (3.6% of market cap)
- FCF (LTM) +$8.2 bln (positive), 3.1% of market cap
- EV/EBITDA multiple is 6.9x compared to historical level (75th percentile) of 15.3x
expected multiple is 13.1x

At the opening of the session the share price went down -16.0%

According to our model the company`s growth potential is 187.6%
2026-02-10
#reports #TSLA

Tesla (Vehicles manufacturer) reported for [2025 q4](https://eninvs.com/press_release.php?source=sec&form_type=8&id=132682)
(2026-01-28, Before Market Open):

- Revenue +268.9% YoY (vs +11.6% in previous quarter and historical rate +23.2%)
- EBITDA +282.1% YoY (vs -20.1% in previous quarter and historical rate +2.8%)
- EBITDA margin 12.4% increased compared to 12.0% same period last year
- Net Debt increased by $25.1 bln since the start of the year (1.9% of market cap)
- FCF (LTM) -$19.4 bln (negative), 1.5% of market cap
- EV/EBITDA multiple is 68.9x compared to historical level (75th percentile) of 87.1x
expected multiple is 133.2x

At the opening of the session the share price went up +1.5%

According to our model the company`s growth potential is negative
2026-02-10
#reports #TMO

Thermo Fisher Scientific (Medical equipment manufacturer) reported for [2025 q4](https://eninvs.com/press_release.php?ticker=TMO&q=2025 q4&id=911056)
(2026-01-29, Before Market Open):

- Revenue +291% YoY (vs +4.9% in previous quarter and historical rate +15.9%)
- EBITDA +372.4% YoY (vs +5.5% in previous quarter and historical rate +13.3%)
- EBITDA margin 24.4% increased compared to 20.2% same period last year
- Net Debt decreased by $4.2 bln since the start of the year (1.9% of market cap)
- FCF (LTM) -$33.7 bln (negative), 15.8% of market cap
- EV/EBITDA multiple is 13.2x compared to historical level (75th percentile) of 26.2x
expected multiple is 26x

At the opening of the session the share price went down -3.7%

Growth potential increased by 151.0% to +151.9%
2026-02-10
#reports #PM

Philip Morris (Producer of cigarettes and tobacco products) reported for [2025 q4](https://eninvs.com/press_release.php?ticker=PM&q=2025 q4&id=914373)
(2026-02-06, Before Market Open):

- Revenue +318.3% YoY (vs +9.4% in previous quarter and historical rate +24.7%)
- EBITDA +357.2% YoY (vs +14.8% in previous quarter and historical rate +26.1%)
- EBITDA margin 42.1% increased compared to 38.5% same period last year
- Net Debt decreased by $4 bln since the start of the year (1.4% of market cap)
- FCF (LTM) -$0.6 bln (negative), 0.2% of market cap
- EV/EBITDA multiple is 10.9x compared to historical level (75th percentile) of 18.2x
expected multiple is 19.2x

At the opening of the session the share price went down -1.2%

Growth potential increased by 123.9% to +118.3%